Hefei R & D Center has more than 40 employees, including 1 doctor, 5 master, 3 senior engineers, the rest of the staff are bachelor degree or above, has a API research center, analysis and testing center, with first-class experimental equipment and instruments and perfect management system, with independent research and development capabilities. The company has established technology platforms such as multiphase drug release system, slow and controlled release preparations, children's drugs, colon localization, inhalation preparations, transdermal drug delivery, etc. The products developed cover all mainstream dosage forms, and has in-depth cooperation and exchanges with domestic research institutions such as Shenyang Pharmaceutical University and Anhui University of Traditional Chinese Medicine.
With clinical benefits as the center, relying on excellent research and development innovation capabilities, Jiexi Pharmaceutical focuses on building product clusters in the fields of cardiovascular and cerebrovascular, endovascular, infection, respiratory and digestive, etc. 11 generic drugs have been approved, among which the key products in the cardiovascular field Metoprolol succinate sustained release tablets and isosorbide mononitrate sustained release capsules have been selected for national collection. The company has established a nationwide investment network, through a rich product system, professional marketing team, good terminal control ability and thoughtful marketing services, and customers hand in hand to win.
In the future, the company adheres to the core values of "integrity, diligence, modesty, cohesion, innovation and sharing", takes "for human health and hope" as its mission, and develops more new drugs and good drugs to benefit more patients.